Research ArticleClinical Studies

Hypofractionated Stereotactic Radiotherapy Using CyberKnife as a Boost Treatment for Head and Neck Cancer, a Multi-institutional Survey: Impact of Planning Target Volume

HIDEYA YAMAZAKI, MIKIO OGITA, KENGO HIMEI, SATOAKI NAKAMURA, KEN YOSHIDA, TADAYUKI KOTSUMA, YUJI YAMADA, MASATERU FUJIWARA, SUNGJAE BAEK and YASUO YOSHIOKA
Anticancer Research October 2014, 34 (10) 5755-5759;

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Local control (LC), progression-free survival (PFS) and overall survival (OS) rates for all patients. The thick line depicts LC rate, thin line depicts PFSrate and dotted line depicts OS rate.

  • Figure 2.
    Figure 2.

    Progression-free survival (PFS) and overall survival (OS) rates according to planning target volume (PTV). Patients with PTV ≤20 cm3 (thick line) showed better PFS rate (92%) and OS rate (100%) than patients with PTV >20 cm3 (dotted line) (61%, p=0.027 and 47% p=0.015, respectively).

Tables

  • Table I.
  • Table II.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Hypofractionated Stereotactic Radiotherapy Using CyberKnife as a Boost Treatment for Head and Neck Cancer, a Multi-institutional Survey: Impact of Planning Target Volume
HIDEYA YAMAZAKI, MIKIO OGITA, KENGO HIMEI, SATOAKI NAKAMURA, KEN YOSHIDA, TADAYUKI KOTSUMA, YUJI YAMADA, MASATERU FUJIWARA, SUNGJAE BAEK, YASUO YOSHIOKA
Anticancer Research Oct 2014, 34 (10) 5755-5759;
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords